Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C
Etsuro Orito(Nagoya City University), Johnson Y.N. Lau(University of Florida), Masamiki Mori(Higashi Osaka City General Hospital), Tomoyoshi Ohno(Nagoya City University), Kaoru Suzuki(Nagoya City University), Ken‐ichi Ohba(Nagoya City University), K. Hayashi(Higashi Osaka City General Hospital), Masashi Mizokami(National Center for Global Health and Medicine), Shiro Iino(University of Fukui), Koji Kato(AbbVie (United States))
Cited by 104
Related Papers
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan
|Hepatology|2001|418
A Case–Control Study for Clinical and Molecular Biological Differences Between Hepatitis B Viruses of Genotypes B and C
|Hepatology|2001|396
High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice
|Hepatology|1994|281
Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C
|Journal of Medical Virology|1994|233